Physician profile
Colleen E Grainger
NPI 1982471306
$1,602.24
in general payments reported to CMS, 2019-2025
22 companies · $1,000 in 2025
The $1,000 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $23.73 · 2024: $579 · 2025: $1,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,602.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,602.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $310.28 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $280.05 | 2024-2025 | |
| Abbott Laboratories | $182.87 | 2024 | Freestyle Libre 3 |
| Astellas Pharma US INC | $146.27 | 2025 | Veozah |
| Exact Sciences Corporation | $124.47 | 2024-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $113.17 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Xeris Pharmaceuticals, INC. | $58.92 | 2024-2025 | Gvoke Hypopen |
| Cranial Technologies, INC | $48.98 | 2025 | Doc Band |
| Otsuka America Pharmaceutical, INC. | $33.79 | 2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $32.80 | 2024 | Eliquis |
| Amgen INC. | $32.19 | 2024-2025 | Otezla, Repatha, Repatha |
| Merck Sharp & Dohme LLC | $32.15 | 2025 | Keytruda |
| Dexcom, INC. | $25.85 | 2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $23.76 | 2025 | |
| Corium, LLC | $23.73 | 2023 | Azstarys |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $23.18 | 2024 | Auvelity |
| Optinose US, INC. | $21.04 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.63 | 2024 | Ofev |
| Phathom Pharmaceuticals, INC. | $19.10 | 2025 | Voquezna |
| Astrazeneca Pharmaceuticals Lp | $18.45 | 2025 | Breztri |
| Janssen Pharmaceuticals, INC | $15.60 | 2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $14.96 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colleen Grainger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.